StockNews.AI
STXS
StockNews.AI
197 days

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

1. Stereotaxis to release Q4 2024 financial results on March 3, 2025. 2. A conference call will be hosted to discuss earnings and corporate updates. 3. Stereotaxis focuses on surgical robotics for minimally invasive interventions. 4. Over 150,000 patients treated worldwide with Stereotaxis technology.

Earnings
+5.53%Current Return
VS
+0.66%S&P 500
$2.3502/03 04:07 PM EDTEvent Start
$2.4802/04 09:52 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

Upcoming earnings report may not significantly alter STXS price, akin to past earnings releases with limited movement.

How important is it?

Earnings announcements can affect stock performance; historical data shows varied impacts.

Why Short Term?

Immediate stock reactions expected around the earnings release date with volatility.

Related Companies

STXS
ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s results and corporate developments. What:Stereotaxis fourth quarter and full year 2024 financial results conference call  When:Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT)  Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 1983976.  Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.  Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. About Stereotaxis Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com. Investor Contacts:David L. FischelChairman and Chief Executive Officer                                                        Kimberly Peery                                                Chief Financial Officer 314-678-6100Investors@Stereotaxis.com

Related News